CSIMarket
 
Adverum Biotechnologies Inc   (ADVM)
Other Ticker:  
 
 
Price: $1.7700 $0.07 4.118%
Day's High: $1.79 Week Perf: -2.21 %
Day's Low: $ 1.65 30 Day Perf: -11.5 %
Volume (M): 1,447 52 Wk High: $ 2.97
Volume (M$): $ 2,561 52 Wk Avg: $1.29
Open: $1.72 52 Wk Low: $0.68



 Market Capitalization (Millions $) 179
 Shares Outstanding (Millions) 101
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -126
 Cash Flow (TTM) (Millions $) 21
 Capital Exp. (TTM) (Millions $) 1

Adverum Biotechnologies Inc
Adverum Biotechnologies Inc is a clinical-stage gene therapy company that focuses on developing novel treatments to treat serious ocular diseases. The company's primary objective is to use gene therapy to provide long-term solutions for patients suffering from conditions such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Adverum aims to deliver its therapies using its proprietary vector platform, which is designed to efficiently and effectively deliver therapeutic genes to the eye. The company is actively engaged in clinical trials and continues to advance its pipeline of potential gene therapies to address unmet medical needs in the field of ophthalmology.


   Company Address: 100 Cardinal Way Redwood City 94063 CA
   Company Phone Number: 656-9323   Stock Exchange / Ticker: NASDAQ ADVM
   ADVM is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Promising Results from Adverum Biotechnologies? LUNA Phase 2 Trial of Ixo-vec in Wet AMD Patients

Published Thu, Feb 8 2024 12:00 PM UTC

Wet age-related macular degeneration (AMD) is a leading cause of vision loss and impairment in the aging population. Currently, treatment options are limited and often burdensome for patients. However, recent developments in gene therapy have shown potential for revolutionizing the management of this debilitating condition. This article aims to discuss the positive prelimina...

Management Announcement

Adverum Biotechnologies Faces Financial Struggles as Latest Financing Raises Questions

Published Mon, Feb 5 2024 12:45 PM UTC

Adverum Biotechnologies' Financing Raises Questions Amidst Substantial Losses
In recent news, Adverum Biotechnologies Inc, a leading biotech company, has announced a private placement financing of $127.5 million. The financing initiative was led by TCGX, with participation from both new and existing investors, including notable firms such as 5AM Ventures, Commodore Cap...

Adverum Biotechnologies Inc

Adverum Biotechnologies Inc. Amplifies Profits for Shareholders with Promising Surge in Q3 Financials, Marking a $34.529 Million Operating Deficit Turnaround

Trailing the leaders in the Biotechnology & Pharmaceuticals sector, a number of lesser-known companies are emerging with their earnings reports. Adverum Biotechnologies Inc, a biotechnology company focused on developing gene therapies, recently announced its operating deficit for the third quarter of 2023. Despite the negative figure of $-34.529 million, this revelation can be seen as a promising development when compared to previous quarters.
In the third quarter of 2022, Adverum Biotechnologies Inc reported an operating deficit of $-41.037 million. The company has managed to reduce this deficit, instilling confidence in market participants regarding its future potential. While Adverum Biotechnologies Inc is still in the process of developing its business strategy, the narrowing of the operating deficit from July to September 2023 to $-32.885 million is a positive sign. This indicates that the company is making progress in managing its finances more effectively, compared to the $-40.131 million deficit reported in the same period in 2022.

Adverum Biotechnologies Inc

Adverum Biotechnologies Inc Makes Strides Towards Profitability as Q2 2023 Operating Shortfall Shrinks to $-31.510 Million

Investors in the stock market have recently received a pleasant surprise when it comes to Adverum Biotechnologies Inc. Despite not expecting any significant increase in revenue during the April to June 2023 reporting cycle, shareholders have been closely monitoring the company's operating shortfall. The good news is that this operating shortfall came in at $-33.065 million, which is an improvement from the previous year's figure of $-44.025 million.
These positive results have given market participants affirmation about ADVM's potential. It is clear that the management of Adverum Biotechnologies Inc has been working hard to make the company more cost-effective and reduce losses. During the second quarter of the 2023 earnings season, the losses were further slashed to $-31.510 million.

Adverum Biotechnologies Inc

Adverum Biotechnologies Inc Faces Declining ROE and Concerns Over Future Prospects

Adverum Biotechnologies Inc has found itself in a precarious position, with a cumulative net loss of $-146 million over the past 12 months resulting in a negative return on equity (ROE) of -73.6%. This performance is concerning, with many investors worried about the company's future prospects. Furthermore, Adverum Biotechnologies Inc's performance is below that of many other similar companies within the Biotechnology & Pharmaceuticals industry, demonstrating a worrying trend.
Despite a slight improvement in the overall ranking of the company's ROE, from 3585 in the fourth quarter of 2022 to 2470 so far in the current quarter, Adverum Biotechnologies Inc has a lot of ground to make up in order to compete with the industry's top players. With no clear path towards profitability in sight, the company's future looks bleak.
Adverum Biotechnologies Inc's first-quarter revenue of $3.6 million may seem like a bright spot, but this is far outweighed by the net loss of $-29.056 million reported in the same period. While this loss is an improvement on the deficit of $-37.908 million reported in the first quarter of the previous year, this is not enough to alleviate concerns around the company's sustainability in the long-term.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com